These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6760 related articles for article (PubMed ID: 2566177)

  • 21. Adoptive transfer and specific active immunization of patients with malignant melanoma.
    Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
    Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma.
    Livingston PO; Cunningham-Rundles S; Marfleet G; Gnecco C; Wong GY; Schiffman G; Enker WE; Hoffman MK
    J Biol Response Mod; 1987 Aug; 6(4):392-403. PubMed ID: 2957470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
    Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
    Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.
    Boerrigter GH; Scheper RJ
    Clin Exp Immunol; 1984 Oct; 58(1):161-6. PubMed ID: 6478648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. M-Vax: an autologous, hapten-modified vaccine for human cancer.
    Berd D
    Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress of immunotherapy in the treatment of malignant melanoma.
    Ariyan S
    Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
    [No Abstract]   [Full Text] [Related]  

  • 27. Cellular immune reactions in patients with bronchogenic carcinoma before and after radio-, chemo- and immunotherapy.
    Gropp C; Havemann K
    Z Immunitatsforsch Immunobiol; 1977 Sep; 153(3):236-47. PubMed ID: 930234
    [No Abstract]   [Full Text] [Related]  

  • 28. [A review on mechanism of anti-tumor action of BCG (author's transl)].
    Tokunaga T
    Kekkaku; 1980 Aug; 55(8):351-7. PubMed ID: 6999202
    [No Abstract]   [Full Text] [Related]  

  • 29. [Medical therapy of malignant melanoma].
    Mini E; Periti P
    Ann Ital Chir; 1989; 60(4):257-63. PubMed ID: 2699710
    [No Abstract]   [Full Text] [Related]  

  • 30. Introduction: Immunotherapy of cancer in man, a reality.
    Klein E
    Natl Cancer Inst Monogr; 1973 Dec; 39():139-61. PubMed ID: 4206961
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy of chronic myelocytic leukemia.
    Sokal JE; Aungst CW; Grace JT
    Natl Cancer Inst Monogr; 1973 Dec; 39():195-8. PubMed ID: 4595316
    [No Abstract]   [Full Text] [Related]  

  • 32. Absence of dependence on cyclophosphamide-sensitive suppressor cells in suppression of cell-mediated immunity by cyclosporine in the guinea pig.
    Thomson AW; Aldridge RD
    Transplantation; 1984 Jul; 38(1):76-7. PubMed ID: 6234688
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 34. [The effect of shigellae on delayed hypersensitivity in mice infected by different routes].
    Borisov VA; Borisova EV; Solov'eva GA
    Mikrobiol Z; 1994; 56(3):55-9. PubMed ID: 7952228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide (author's transl)].
    Terashima M
    Hokkaido Igaku Zasshi; 1980 Nov; 55(6):495-9. PubMed ID: 6456215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCG immunotherapy in Burkitt's lymphoma: preliminary results of a randomized clinical trial.
    Ziegler JL; Magrath IT
    Natl Cancer Inst Monogr; 1973 Dec; 39():199-202. PubMed ID: 4595317
    [No Abstract]   [Full Text] [Related]  

  • 38. Active immunotherapy with B.C.G. for melanoma.
    Thompson RB
    Panminerva Med; 1975; 17(5-6):189-92. PubMed ID: 1161318
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunotherapy of guinea pig cancer with BCG.
    Zbar B
    Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy and immune competence of patients with malignant melanoma.
    Kovarík J; Ninger E; Mechl Z; Zemanová D; Lauerová L; Sopková B; Svejda J; Bacovský B; Bártová A; Bártek J
    Czech Med; 1983; 6(3):172-4. PubMed ID: 6416794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 338.